Abstract

Prostate cancer is the second most commonly occurring cancer in men and the fourth most commonly occurring cancer overall. There were 1.3

million new cases in 2018. The top 20 countries with the highest rates of prostate cancer in 2018 include UK and France. The prostate cancer has

become the second most common cancer of urinary system in China. Consequently, there’s no doubt that bladder cancer and prostate cancer have

been two leading killers in urinary system, here, we define them as “neo two cancers” with “neo” prefixed to make it distinguished from women’s

two most common cancers, breast cancer and cervical cancer. Early detection is the major challenge. We established a highly sensitive method

to detect cancer antigen in urine using LS-MS-MS screening (US patent and published in Mol cancer, cancer+, Clin Cancer Res, Eur Urol, and

Cancer Res). The goal of the study is to develop affordable, accurate and non-invasive technology available to the World through collaborations.